Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France

Completed

Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

- Patients aged ≥ 18 years
- Diagnosed with non valvular atrial fibrillation (NVAF)
- Prescribed with a newly initiated AC treatment (apixaban, other NOACs or VKAs). Newly initiated AC treatment is defined as any AC treatment initiated within the past 3 months, including day of enrolment

Exclusion Criteria

- Patients with atrial fibrillation (AF) due to reversible causes
- Patients with a diagnosis of VAF. The term VAF is used to imply that AF is related to rheumatic valvular disease (predominantly mitral stenosis) or prosthetic heart valves
- Patients participating in an ongoing clinical trial in AF